What are the long-term cognitive outcomes of pediatric-onset multiple sclerosis, and are they different from those observed in the more common adult-onset multiple sclerosis?
This nationwide cohort study included 5704 persons with definite multiple sclerosis (300 of whom had pediatric-onset disease) and 46 429 prospectively collected cognitive test scores. Patients with pediatric-onset multiple sclerosis exhibited reduced information-processing efficiency and were more likely to experience cognitive impairment in this domain than their counterparts with adult-onset disease, independent of age or disease duration.
Pediatric-onset multiple sclerosis appears to render persons particularly susceptible to impairments in information processing in adulthood; children and adolescents who develop multiple sclerosis should be monitored closely for cognitive changes and helped to manage the potential challenges that early-onset multiple sclerosis poses for cognitive abilities later in life.
Cognitive impairment in multiple sclerosis (MS) can lead to reduced quality of life, social functioning, and employment. Few studies have investigated cognitive outcomes among patients with pediatric-onset MS (POMS) over the long term.
To compare long-term information-processing efficiency between patients with POMS and adult-onset MS (AOMS).
Design, Setting, and Participants
This population-based longitudinal cohort study accessed the Swedish MS Registry (SMSreg), which collates information from all 64 neurology clinics in Sweden. Registered cases with definite MS in the SMSreg with an onset before April 15, 2018, and at least 2 Symbol Digit Modalities Test (SDMT) scores recorded were included. Only persons aged 18 to 55 years and with duration of disease of less than 30 years at the time of SDMT administration were included, to ensure comparable ranges between patients with POMS and AOMS. Of 8247 persons with an SDMT recorded in the SMSreg, 5704 met inclusion criteria, 300 (5.3%) of whom had POMS. Data were collected from April 1, 2006, through April 15, 2018 and analyzed from April through August 2018.
Pediatric-onset MS (onset <18 years of age) vs AOMS (onset ≥18 years of age).
Main Outcomes and Measures
Information-processing efficiency measured every 6 or 12 months by the SDMT. Linear mixed-effects models were used to compare all available SDMT scores between patients with POMS and those with AOMS. Persons with cognitive impairment (ever vs never) were identified using regression-based norms and compared between POMS and AOMS groups using logistic regression.
Of the 5704 participants, 4015 were female (70.4%), and 5569 had a relapsing-onset disease course (97.6%). Most participants were exposed to a disease-modifying therapy (DMT) during follow-up (98.8%). Median age at baseline for the POMS group was 25.6 years (interquartile range, 21.0-31.7 years) and for the AOMS group, 38.3 years (interquartile range, 31.4-45.2 years). A total of 46 429 unique SDMT scores were analyzed. After adjustment for sex, age, disease duration, disease course, total number of SDMTs completed, oral or visual SDMT form, and DMT exposure, the SDMT score for patients with POMS was significantly lower than that of patients with AOMS (β coefficient, −3.59 [95% CI, −5.56 to −1.54]). The SDMT score for patients with POMS declined faster than that of patients with AOMS (β coefficient, −0.30 [95% CI, −0.42 tp −0.17]). The odds of cognitive impairment were also significantly elevated in the POMS group (odds ratio, 1.44; 95% CI, 1.06-1.98).
Conclusions and Relevance
In adulthood, patients with POMS demonstrated a more rapid reduction in information-processing efficiency over time and were more likely to experience cognitive impairment than patients with AOMS, independent of age or disease duration. Further investigation is required to understand the mechanisms by which early MS onset influences cognitive outcomes.
McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J. Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. JAMA Neurol. Published online June 17, 2019. doi:10.1001/jamaneurol.2019.1546
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: